What Is The NTAP Breakthrough Device Designation?

The New Technology Add-on Payment (NTAP) program, established in 2001, provides supplemental Medicare payments to hospitals for certain new, high-cost technologies during their initial market years (typically up to three years). These payments help offset the gap between the technology’s cost and standard Medicare Severity-Diagnosis Related Group (MS-DRG) reimbursement to the hospital.

To qualify under the traditional pathway, technologies must meet three criteria:

• Newness: Not substantially similar to existing options.
• Cost: The technology must be significantly more costly than the MS-DRG payment.
• Substantial Clinical Improvement (SCI): Demonstrated meaningful benefits in clinical outcomes for Medicare beneficiaries.

In 2020 (finalized for FY 2021), CMS created an alternative pathway for devices with FDA Breakthrough Device designation. These transformative technologies—intended for life-threatening or irreversibly debilitating conditions—could qualify for NTAP by meeting newness and cost criteria, with SCI presumed based on the FDA’s expedited review and designation. This streamlined access aimed to accelerate adoption while real-world evidence developed.

The Breakthrough Devices Program itself, run by the FDA, expedites development, assessment, and review for devices offering significant advantages over existing options.

What Is The FDA Breakthrough Device Program?

The Breakthrough Devices Program, is a voluntary, expedited pathway for medical devices and device-led combination products that offer the potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Established under the 21st Century Cures Act, it provides manufacturers with prioritized review, interactive FDA engagement, and other resources to speed development, assessment, and market authorization while still requiring devices to meet the agency’s rigorous standards for safety and effectiveness.

Devices must demonstrate that they provide a more effective solution for serious conditions and meet at least one additional criterion—such as representing a breakthrough technology, offering significant advantages over existing alternatives (including potential reductions in hospitalization, improved quality of life, or long-term efficiencies) or addressing an unmet need with no other options available.

This FDA designation was the basis for CMS’s alternative NTAP pathway (introduced for FY 2021), which presumed “substantial clinical improvement” (SCI) based on the FDA’s determination of transformative potential. The logic was straightforward: if the FDA had already rigorously evaluated the device as offering significant advantages for high-need patients, a redundant, separate CMS evaluation of SCI would create unnecessary duplication and delay patient access to promising innovations.

Why Repeal The Alternative Pathway? CMS’s Rationale

CMS now argues that experience with the alternative pathway has revealed limitations in the evaluation process. Many devices approved via this route have not, in retrospect, consistently demonstrated substantial clinical improvement relative to existing technologies. For instance, analyses of breakthrough-designated devices have highlighted cases where FDA authorization relied heavily on surrogate endpoints, smaller studies, or limited comparative data—leading to post-market questions about real-world clinical benefits and cost-effectiveness for Medicare populations. One illustrative concern raised in broader evaluations involves certain AI-enabled diagnostic or procedural tools that secured breakthrough status and NTAP eligibility but later faced scrutiny for marginal outcome improvements over standard care in large-scale use.

Requiring all applicants to meet the full traditional criteria—including robust SCI evidence—would better protect Medicare beneficiaries and ensure taxpayer dollars support truly superior innovations. Critics of the current pathway highlight risks of over-adoption of promising-but-unproven technologies, potential for higher overall costs without proportional outcome gains, and the need for stronger evidence-based decision-making in an era of fiscal pressure on Medicare. A more uniform, rigorous standard aligns reimbursement more closely with proven value, potentially curbing wasteful spending.

Why Preserve (or Strengthen) Access For Breakthrough Technologies?

Conversely, eliminating the alternative pathway risks slowing patient access to meaningful innovations, particularly in fields like spine surgery where complex pathologies demand rapid iteration. Many breakthrough devices address unmet needs in high-risk populations (e.g., scoliosis spinal deformity, revisions, or motion preservation), where generating large-scale randomized evidence pre-market is challenging due to ethical, time, and rarity considerations.

Physician judgment, informed by emerging data, FDA oversight, and individual patient factors, should play a central role. Overly restrictive policies can delay adoption, stifle small innovators and ultimately harm patients waiting for better options. As noted by groups like AdvaMed and societies such as ISASS, the pathway has facilitated timely access while evidence matures.

In spine care, technologies like advanced interbody devices, navigation systems, or novel instrumentation often demonstrate incremental but clinically relevant benefits (e.g., reduced complications, faster recovery) that may not immediately meet the strictest SCI thresholds in early data.

How Can Medicare Handle New Technology?

Medicare should prioritize a balanced, market-oriented approach that accelerates meaningful innovation while maintaining rigorous accountability and fiscal responsibility. The agency has already taken several positive steps in this direction, demonstrating a willingness to evolve beyond rigid, one-size-fits-all models.

Positive recent technology developments include:

• Continued support for NTAP overall: For FY 2027, CMS proposes to continue add-on payments for 41 technologies, with an estimated increase of approximately $464 million in supplemental payments, while approving select new applications under traditional criteria—showing the core program remains a viable bridge for high-value innovations.
• Launch of the RAPID program: In April 2026, CMS and FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. This initiative aligns regulatory and coverage processes earlier, enabling national Medicare coverage decisions within 60–90 days of FDA authorization for eligible breakthrough devices addressing unmet needs in Medicare populations. It reduces the traditional coverage gap and supports faster, evidence-informed adoption.
• Growing emphasis on real-world evidence and value-based elements: CMS increasingly incorporates post-market data, registries, and broader outcome measures in decision-making.

Building on these strengths, Medicare should refine its technology framework as follows:

• Evidence Tiering and Post-Market Data: Maintain flexible pathways for promising devices with conditional or transitional payments tied to real-world evidence collection (e.g., registries, pragmatic trials, or ongoing studies). The new RAPID program is a strong step forward here, as it synchronizes FDA and CMS evidence requirements from the investigational phase onward, allowing pivotal trials to support both approval and coverage simultaneously.
• Value-Based Metrics: Expand beyond traditional Substantial Clinical Improvement (SCI) to incorporate patient-reported outcomes (PROs), reduced revision rates, shorter lengths of stay, functional improvements, and total cost-of-care savings. CMS has already advanced PRO-based performance measures (PRO-PMs) in various models, including in orthopedic and spine-related procedures; applying similar tools to new technology evaluations would better capture real patient benefit, especially in spine surgery where quality-of-life gains and motion preservation matter deeply.
• Transparency and Predictability: Deliver clear, timely NTAP decisions with robust appeals processes and predictable payment amounts. This reduces financial uncertainty for hospitals adopting costly innovations and encourages broader uptake of technologies that ultimately improve outcomes.

Blanket repeal of the alternative NTAP pathway risks tilting the balance too far toward caution, potentially creating a lag for innovative devices in complex fields like spine deformity. Instead, CMS should refine—not eliminate—targeted incentives, ensuring patients continue to benefit from evidence-driven policies.